Stock Ratings | Loop Capital maintained its "buy" recommendation on Nvidia (NVDA) stock and raised its price target from $250 to $350; Goldman Sachs also maintained its "buy" recommendation on Nvidia stock.
Caribou Biosciences, Inc. CRBU | 1.90 | +10.47% |
MoonLake Immunotherapeutics Class A MLTX | 18.64 | +10.10% |
RAPT Therapeutics RAPT | 58.02 | Delist |
Kalaris Therapeutics, Inc. KLRS | 5.77 | +8.87% |
PLUS THERAPEUTICS INC PSTV | 0.16 | -24.23% |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Citigroup: Maintaining Caribou Biosciences' ( Caribou Biosciences(CRBU.US) ) rating at "Buy", while raising the target price from $5 to $8.
HC Wainwright & Co.: Upgrades MoonLake Immunotherapeutics - Class A Ordinary Shares ( MoonLake Immunotherapeutics - Class A Ordinary Shares(MLTX.US) ) to "Buy", with a target price of $30.
Wells Fargo: Maintaining RAPT Therapeutics(RAPT.US) Therapeutics' rating at "Overweight", while raising the price target from $48 to $72.
Citizens: Initial rating for Kalaris Therapeutics ( Kalaris Therapeutics Inc. Ordinary Shares(KLRS.US) ) at "Outperform," with a price target of $20.
HC Wainwright & Co.: Maintaining a "buy" rating on Plus Therapeutics ( PLUS THERAPEUTICS INC(PSTV.US) ), while lowering the price target from $3 to $2.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| Caribou Biosciences(CRBU.US) | to lift | $8.0 | $2.43 | 229.22% | Citigroup |
| MoonLake Immunotherapeutics - Class A Ordinary Shares(MLTX.US) | to lift | $30.0 | $10.2 | 194.12% | HC Wainwright & Co. |
| RAPT Therapeutics(RAPT.US) | to lift | $72.0 | $29.35 | 145.32% | Wells Fargo |
| Iris Energy Limited(IREN.US) | to lift | $142.0 | $67.75 | 109.59% | Cantor Fitzgerald |
| Ardelyx, Inc.(ARDX.US) | to lift | $11.0 | $5.92 | 85.81% | Citigroup |
| Kalaris Therapeutics Inc. Ordinary Shares(KLRS.US) | Initial classification | $20.0 | $4.99 | 300.8% | Citizens |
| PLUS THERAPEUTICS INC(PSTV.US) | cut | $2.0 | $0.5177 | 286.32% | HC Wainwright & Co. |
| Newell Brands Inc(NWL.US) | cut | $7.0 | $3.225 | 117.05% | Canaccord Genuity |
| Charter Communications, Inc. Class A(CHTR.US) | cut | $425.0 | $222.2 | 91.27% | Benchmark |
| Emerald Expositions Events, Inc.(EEX.US) | cut | $7.7 | $4.24 | 81.6% | Rosenblatt |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
JP Morgan: Maintaining AbbVie's ( AbbVie, Inc.(ABBV.US) ) rating at "overweight", while raising the price target from $250 to $260.
Mizuho: Maintaining Coinbase Global's ( Coinbase(COIN.US) rating at "neutral", while raising the price target from $300 to $320.
Canaccord Genuity: Maintain Datadog's ( Datadog(DDOG.US) ) rating at "Buy", while raising the target price from $160 to $185.
Cantor Fitzgerald: Maintaining Iris Energy Limited(IREN.US) Energy Limited's rating at "overweight", while raising the price target from $100 to $142.
Canaccord Genuity: Maintaining a "buy" rating on Strategy ( Strategy (MSTR.US) ) stock, while raising the price target from $464 to $474.
Loop Capital: Maintaining a "buy" rating on NVIDIA NVIDIA Corporation(NVDA.US) ) stock, while raising the price target from $250 to $350.
Goldman Sachs: Maintaining a "buy" rating on NVIDIA NVIDIA Corporation(NVDA.US) ) stock, while raising its price target from $210 to $240.
Citigroup: Maintaining Xcel Energy ( Xcel Energy Inc.(XEL.US) ) rating at "Buy", while raising the price target from $80 to $92.
Scotiabank: Maintaining Exxon Mobil's ( Exxon Mobil Corporation(XOM.US) ) rating at "Outperforming the Market," while raising its price target from $128 to $155.
First Coverage
Citigroup: Initial rating for Alliance Laundry Holdings ( Alliance Laundry Holdings, Inc.(ALH.US) ) at "buy", with a target price of $32.
Aletheia Capital: Initial rating for Amkor Technology, Inc.(AMKR.US) at "buy", with a target price of $62.
Craig-Hallum: Initial rating for Apogee Therapeutics ( Apogee Therapeutics(APGE.US) ) at "buy", with a target price of $109.
Jefferies: Initial rating for Chime Financial ( Chime Financial, Inc.(CHYM.US) ) at "Hold", with a price target of $17.
CIBC: Datadog ( Datadog(DDOG.US) ) stock has a preliminary rating of "neutral", with a price target of $170.
RBC Capital: Initial rating for Revolution Medicines ( Revolution Medicines(RVMD.US) ) at "outperform", with a target price of $77.
Rothschild: Initial rating for Schlumberger ( Schlumberger NV(SLB.US) ) stock at "buy", with a target price of $48.
UBS: Solstice Advanced Mat ( Sollensys Corp.(SOLS.US) ) has a preliminary rating of "buy" on its stock, with a target price of $62.
reduction
Keefe, Bruyette & Woods: Maintaining the rating of Arbor Realty Trust ( Arbor Realty Trust, Inc.(ABR.US) ) at "Market Match," while lowering the target price from $12 to $11.
Citigroup: Maintaining a "neutral" rating on AGCO ( AGCO Corporation(AGCO.US) ), while lowering the price target from $120 to $115.
Truist Securities: Affirming the "Buy" rating on AGCO ( AGCO Corporation(AGCO.US) ), with a price target reduced from $142 to $123.
UBS: Maintaining a "neutral" rating on Cava Group CAVA Group Inc.(CAVA.US) , while lowering the price target from $75 to $61.
Goldman Sachs: Maintaining a "buy" rating on Ryan Specialty Holdings Ryan Specialty Group Holdings, Inc.(RYAN.US) , while lowering the price target from $71 to $63.
Citigroup: Maintaining its rating on Schneider National ( Schneider National, Inc. Class B(SNDR.US) ) at "neutral", while lowering its price target from $25 to $23.
Truist Securities: Stryker ( Stryker Corporation(SYK.US) ) affirmed its "Hold" rating, lowering its price target from $407 to $392.
Citigroup: Maintaining a "buy" rating on Linde ( Linde plc Ordinary Share(LIN.US) , while lowering the price target from $535 to $520.
Roth Capital: Confirming its "Buy" rating on LKQ ( LKQ Corporation(LKQ.US) ), with a price target cut from $46 to $43.
Wells Fargo: Maintaining LyondellBasell's LyondellBasell Industries NV(LYB.US) ) rating at "overweight", while lowering the price target from $65 to $55.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.